natgillin/translations-raw huggingface dataset:
The pharmaceutical formulation for use according to claim 8, wherein in the method the pharmaceutical composition is administered in combination with Trastuzumab. 
Farmaceutska formulacija za uporabu prema zahtjevu 8, naznačena time, da se u tom postupku, farmaceutska formulacija daje u kombinaciji s Trastuzumabom.
The grooming tool of clause 5 wherein the head includes a locking tab arrangement constructed and arranged to releasably lock the blade carrier in at least the first position and the second position. The grooming tool of clause 6 wherein: the blade carrier includes first and second grooves therein; and 
Alat za njegu (10) u skladu s patentnim zahtjevom 3, naznačen time što glava (14) ima sklop zabravljujućih jezičaca (86) takve konstrukcije i smještaja da odvojivo zabravljuju nosač oštrica (30) u najmanju ruku prvom položaju i drugom položaju.
The liposome of claim 7, wherein the RNA molecule has two open reading frames, the first of which encodes an alphavirus replicase and the second of which encodes the immunogen. 
Liposom u skladu s patentnim zahtjevom 9, naznačen time što samoreplicirajuća molekula RNA ima dva otvorena okviri čitanja, od kojih prvi kodira alfavirusnu replikazu, a drugi kodira imunogen.
The method according to claim 2, wherein the vibroacoustic signals emitted inside the pipeline (12) and registered by the measurement stations (14) are temporally synchronized through an absolute time reference system (16). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što su vibroakustični signali odaslani unutar cjevovoda (12) i snimljen na mjernim postajama (14) vremenski sinkronizirani preko apsolutnog vremenskog referentnog sustava (16).
The radio communication terminal apparatus according to claim 1, wherein the transmitter, in operation, transmits the A-SRS in response to a specific combination of a type of the control information including the transmission request and a bit value of the transmission request. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 1, naznačen time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon primanja kontrolne informacije višeg sloja.
A mixing member as claimed in claim 1, wherein said scraper is made of plastic or metal. 
Članak za miješanje prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je navedeni strugač (8) izrađen iz plastike ili metala.
The actuator mechanism 118 of the first dose counter is shown schematically in Figure 5, together with the gear wheel in the form of a ratchet-toothed wheel 130. 
Brojač doza u skladu s patentnim zahtjevom 1, pri čemu je kotač sa zupčanikom koji je postavljen za pokretanje drugog pogona zapornog zaklopca (132) prvi kotač sa zupčanikom (30).
3' ACUUCCCACUUUAUAAGAG 5' (sense strand) wherein each of A, C, U and G is an unmodified ribonucleotide or a 2'-O-methyl) sugar modified ribonucleotide and each consecutive ribonucleotide is joined to the next ribonucleotide by a covalent bond; wherein in the antisense strand the first, third, fifth, seventh, ninth, eleventh, thirteenth, fifteenth, seventeenth and nineteenth ribonucleotide is a 2'-O-methyl sugar modified ribonucleotide; and wherein in the sense strand the second, fourth, sixth, eighth, tenth, twelfth, fourteenth, sixteenth and eighteenth ribonucleotide is a 2'-O-methyl sugar modified ribonucleotide. 
Spoj dvolančane siRNK za primjenu prema bilo kojem od zahtjeva 1-5, pri čemu taj spoj siRNK ima sljedeću strukturu: 5* UGAAGGGUGAAAUAUUCUC 3 (protusmisleni lanac) 3" ACUUCCCACUUUAUAAGAG 5? (smisleni lanac) naznačen time da je svaki od A, C, U i G neki nemodificirani ribonukleotid ili ribonukleotid modificiran u 2-O-metil šećeru i da je svaki uzastopni ribonukleotid kovalentnom vezom spojen na sljedeći ribonukleotid; naznačen time da je u protusmislenom lancu prvi, treći, peti, sedmi, deveti, jedanaesti, trinaesti, petnaesti, sedamnaesti i devetnaesti ribonukleotid neki ribonukleotid modificiran u 2"-O-metil šećeru; i naznačen time da je u smislenom lancu drugi, četvrti, šesti, osmi, deseti, dvanaosti, četrnaesti, šesnaosti i osamnaesti ribonukleotid neki ribonukleotid modificiran u 2'-O-metil šećeru.
The method according to claim 7, wherein the coating composition further comprises a functional additive. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što pokrovna smjesa dodatno sadrži funkcionalni aditiv.
Compound (I), wherein the partial structural formula: 
Spoj temeljem zahtjeva 1, pri čemu djelomična strukturna formula:
Consistently, the present invention provides a novel process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid and hemipentahydrate monosodium salt thereof. 
Sažetak izuma Ovaj izum pribavlja novi postupak za pripravu [1-hidroksi-2-(3-piridiniljetiliden] bisfosfonske kiseline i njene hemipentahidratne mononatrijeve soli.
C1-C24 alkyl, 2- to 20 membered heteroalkyl, C3-C8 cycloalkyl, 4- to 8-membered heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from: 
C1-C24 alkil, 2-člani do 20-člani heteroalkil, C3-C8 cikloalkil, 4-člani do 8-člani heterocikloalkil, aril, i heteroaril, supstituiran barem jednim supstituentom koji je odabran iz niza koji čine:
mg of ET-743 was added to a compounding glass vessel and dissolved by magnetical stirring in 1080 ml wfi+3,240 mL phosphoric acid 1N for approximately 1 h (dissolution was checked visually). 
141.21 mg ET-743 dodano je u staklenu bocu za miješanje i otopljeno magnetnim miješanjem u 1080 ml wfi + 3,240 mL fosforne kiseline 1 N približno 1 sat (otapanje je provjeravano vizualno).
raising the pH of a solution containing the protein or contacting the recovered protein with a catalytic amount of elastase to produce a mature type I elastase protein, thereby producing a mature type I elastase protein. 
(b) uvjeti aktivacije obuhvaćaju dodavanje katalitičke količine elastaze u otopinu koji sadrži autoaktivacijski protein proelastazu; i/ili
A T cell genetically engineered to express a CAR, wherein the CAR comprises (a) an antigen binding domain that is an anti-CD19 scFv, (b) a costimulatory 4-1BB signaling region, and (c) a CD3 zeta signaling domain, for use in a method for treating cancer that comprises administering said T cell to a human diagnosed with cancer, wherein the anti-CD19 scFv comprises the amino acid sequence of SEQ ID NO:20 or the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO:24, and wherein said method generates a population of genetically engineered T cells that persists in the human for at least eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration, and wherein the human is resistant to at least one chemotherapeutic agent. 
T stanica koja je genetski konstruirana tako da eksprimira CAR, naznačena time što CAR sadrži (a) antigen vezujuću domenu koja je anti-CD19 scFv, (b) kostimulatorno signalno područje 4-1BB, i (c) signalnu domenu CD3 zeta za upotrebu u postupku za liječenje raka koji obuhvaća primjenu navedene T stanice kod čovjeka kojem je dijagnosticiran rak, pri čemu anti-CD19 scFv sadrži aminokiselinsku sekvencu prema SEQ ID NO:20 ili signalnu domenu CD3 zeta sadrži aminokiselinsku sekvencu prema SEQ ID NO:24, i pri čemu navedeni postupak stvara populaciju genetski konstruiranih T stanica koje perzistiraju u čovjeku najmanje osam mjeseci, devet mjeseci, deset mjeseci, jedanaest mjeseci, dvanaest mjeseci, dvije godine, ili tri godine nakon primjene, i pri čemu je čovjek otporan na liječenje najmanje jednim kemoterapijskim sredstvom.
Concentrated aqueous ammonia (15 ml) was added, and the solution heated to 50°C with stirring for 2 hours, causing precipitation of a cream coloured solid. 
Potom je dodan koncentrirani tekući amonijak (15 ml). i otopina je zagrijana na 50 *C uz miješanje tijekom dva sata, što je dovelo do taloženja krutine krem-boje.
A bispecific antibody according to any one of claim 1 to 5, characterized in that amino acid 124 is K, amino acid 147 is E, amino acid 213 is E, and amino acid 123 is R. 
Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, što je amino-kiselina 124 K, aminokiselina 147 je E, amino-kiselina 213 je E i amino-kiselina 123 je R.
Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Uporaba prema patentnom zahtjevu 1, naznačena time što su kognitivni poremećaji 1 bolesti povezani s RyR izabrani iz grupe koju čine Alzheimerova bolest, oblici gubitka pamćenja i gubitak pamćenja ovisan o starosti.
administering to said individual a therapeutically effective amount of phosphatidylcholine, thereby ameliorating at least one symptom of said ulcerative colitis. Phosphatidylcholine for use in the method of claim 1, wherein said phosphatidylcholine is administered in a delayed release oral formulation, wherein, preferably, the delayed release is pH-dependent, wherein, preferably, the pH-dependent delayed release formulation comprises a gastric acid resistant substance, wherein the gastric acid resistant substance is preferably selected from the group consisting of film covershields and carrier matrices, or wherein the gastric acid resistant substance comprises preferably acrylpolymers, wherein said acrylpolymer is preferably Eudragit, more preferably Eudragit S100, or wherein said acrylpolymer is Eudragit L30, wherein, preferably, the pH-dependent delayed release oral formulation comprises about 500 mg phosphatidylcholine. 
Fosfatdilkolin za uporabu u postupku prema zahtjevu 1, naznačen time, da se spomenuti fosfatdilkolin primjenjuje kao oralna formulacija s odgođenim otpuštanjem, pri čemu je poželjno da je odgođeno otpuštanje ovisno o pH-vrijednosti, pri čemu je poželjno da formulacija s odgođenim otpuštanjem ovisnim o pH-vrijednosti, sadrži tvar otpornu na želučanu kiselinu, gdje je tvar koja je otporna na želučanu kiselinu poželjno odabrana iz skupine koju čine zaštitni film-omotači i matrice-nosači, ili gdje tvar otporna na želučanu kiselinu sadrži poželjno akrilpolimere, pri čemu je spomenuti akrilpolimer poželjno Eudragit, još bolje Eudragit $100 ili gdje je spomenuti akrilpolimer Eudragit L30, dok oralna formulacija koja ima odgođeno otpuštanje ovisno o pH-vrijednosti, poželjno sadrži oko 500 mg fosfatdilkolina.
The method of preparation of alkenyl triphenylphosphonium derivatives of tamoxifen of the general formula IA is based on preparation of ylide generated from alkyl bis (triphenylphosphonium) of the general formula VIII 
O LO IV, gdjen=5do9 na silirani derivat opće formule IV djeluje tetrabutilamonij fluorid pri nastanku alkenola opće formule V, o 5
Thus, specific lozenges according to the invention can be made, for example, by combining a 70% solution of non-crystallising sorbitol, xylitol and gum acacia, dissolving in water and heating to a temperature of approximately 113-117° C., for example 114° C. Heating may be achieved by direct heat transfer, for example, using a jet heater or by indirect heating using a heat exchange surface. 
Poslije kalupljenja može se izvesti dodatni korak koji sadrži sušenje tableta. Tako, specifične tablete prema izumu se mogu pripremiti, na primjer, spajanjem 70% otopine ne-kristalizirajućeg sorbitola, ksilitola i gume akacije, otopanje u vodi i zagrijavanje do temperature od približno 113-117%C, na primjer 114*C.
In particular in one preferred embodiment of the invention, the predetermined breaking edge may be situated on a straight line which extends through the midpoint of the disk-like element. 
Upotreba u skladu s patentnim zahtjevom 8, naznačena time, da je lomni rub (14) postavljen na ravnoj liniji koja prolazi kroz središte elementa u obliku diska (7,8).
3-(1,3-Benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)pyridazine and salts and solvates thereof, preferably pharmaceutically acceptable salts and solvates thereof. 
Sim o e Spoj, naznačen time, da je to 3-(1,3-benzodioksol-5-il)-6-(4-ciklopropilpiperazin-1-iDpiridazin ili njegova farmaceutski prihvatljiva sol ili solvat.
or a pharmaceutically acceptable salt thereof, wherein: is H or (1-6C alkyl); 
R? ili njegova farmaceutski prihvatljiva sol, naznačen time da: R' je Hili (1-6C alkil);
A method for preparing a site-specific physiologically active polypeptide conjugate, comprising the steps of: treating a physiologically active polypeptide with a non-peptidyl polymer in a reaction medium which contains a specific amount of an alcohol and has a specific pH to enable the non-peptidyl polymer to bind to a target site of the physiologically active polypeptide; 
obrada fiziološki djelotvornog polipeptida s nepeptidilnim polimerom u reakcijskom mediju koji sadrži specifičnu količinu alkohola i ima specifični pH za omogućavanje nepeptidilnom polimeru vezanje na ciljano mjesto od fiziološki djelotvornog polipeptida; i ii) izolacija i pročišćavanje konjugata fiziološki djelotvornog polipeptida iz reakcijske smjese iz koraka i) putem kromatografske ionske izmjene korištenjem alkohola, pri čemu fiziološki djelotvorni polipeptid je eksendin, inzulin, oksintomodulin, GLP-1, GLP-2, grelin, kalcitonin, ili jedan od njihovih derivata koji imaju bilo koju od struktura odabranih od sljedećih formula od (I) do (IV):
The compound of Formula LXV can be deformylated to form a compound of Formula LXVI. 
Formula XIII čime se dobiva spoj Formule XLVIII: reakciju spoja Formule XLVIII sa spojem Formule XV:
Returning the filtered water to said at least one containing means; Utilizing said treated water in at least one downstream industrial process; wherein the coordination means vary the flow of treated water to the downstream industrial process based on information (12) such as output or production rate. 
vraćanje filtrirane vode u navedena najmanje jedna sredstva za zadržavanje; e. = korištenje navedene obrađene vode u najmanje jednom nizvodnom industrijskom postupku; pri čemu sredstva za koordinaciju mijenjaju protok obrađene vode prema nizvodnom industrijskom procesu na temelju informacija (12) kao što je izlazna ili proizvodna brzina.
An antibody or an antigen binding fragment thereof capable of specific binding to Kidney associated antigen 1 (KAAG1), wherein the antibody or antigen binding fragment thereof: comprises a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:35, SEQ ID NO.:36 or SEQ ID NO.:37 and/or a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:30, SEQ ID NO.:31 or SEQ ID NO.:32 or; 
Humanizirano protutijelo ili njegov fragment koji veže antigen, naznačeno time, da je sposobno za specifično vezanje na antigen 1 povezan s bubregom (KAAGI), pri čemu humanizirano protutijelo ili njegov fragment koji veže antigen posjeduje varijabilno područje teškog lanca koje ima aminokiselinsku sekvencu kako je prikazano u SEQ ID NO:35, SEQ ID NO:36 ili SEQ ID NO:37, te varijabilno područje lakog lanca koje ima aminokiselinsku sekvencu kako je prikazano u SEQ ID NO:30, SEQ ID NO:31 ili SEQ ID NO:32.
A composition according to claim 28, which, in addition to comprising the compound of formula (I), comprises a further herbicide as mixing partner and a safener. 
Sastav, prema zahtjevu 30, naznačen time, da dodatno uz sadržaj spoja formule (I) obuhvaća neki drugi herbicid za sudjelovanje u mješavini i zaštitno sredstvo.
The support leg of claim 1, wherein the support leg comprises exactly one rotating shaft, connected in a kinematic mechanism with the maneuvering screw (5), the rotating shaft being the drive shaft (8). 
Nosivi krak prema zahtjevu 1, naznačen time, da on ima točno samo jednu rotacijsku osovinu koja je spojena na kinematički mehanizam s manevarskim vijkom (5), pri čemu ta rotacijska osovina je pogonska osovina (8).
Method for processing of pozzolans in the form of fly ash such as Class F and/or Class C fly ash used for preparation of mortars and concretes, wherein in the fly ash crystalline or quasi-crystalline phases, so called scoria, were formed, characterized in that the pozzolan is subjected to a high energetic mechanical processing by means of grinding in a grinding equipment so that the final product has the following particle size distribution: 
HR P20190526 T1 PATENTNI ZAHTJEVI Postupak za obradu pucolana u obliku letećeg pepela, kao što je leteći pepeo klase F i/ili klase C koji se koristi za pripremu mortova i betona, pri čemu su u letećem pepelu nastale kristalne ili kvazi-kristalne faze, takozvana troska, naznačen time što se pucolan podvrgava visoko energetskoj mehaničkoj obradi mljevenjem u opremi za mljevenje tako da konačni proizvod ima sljedeću raspodjelu veličine čestica:
a light chain variable domain sequence selected from the group consisting of; 
varijabilnu domenu lakog lanca izabranu iz grupe koja sadrži:
The recombinant RhCMV or HCMV vector or the composition of claim 13, wherein the infectious disease caused by human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), human cytomegalovirus (HCMV), hepatitis C, papillomavirus, Plasmodium, Kaposi's sarcoma associated herpesvirus, Varicella zoster virus, Ebola virus, Mycobacterium tuberculosis, Chikungunya virus, dengue virus, monkeypox virus, herpes simplex 1, herpes simplex 2, Epstein-Barr virus (EBV), poliovirus, influenza virus, or Clostridium tetani. 
Rekombinantni vektor RhCMY ili HCMY ili pripravak u skladu s patentnim zahtjevom 13, naznačen time što zaraznu bolest uzrokuje virus humane imunodeficijencije (HIV), virus majmunske imunodeficijencije (SIV), ljudski citomegalovirus (HCMV), hepatitis C, papilomavirus, plazmodij, herpesvirus povezan s Kaposijevim sarkomom, virus varicela-zoster, virus ebole, Mycobacterium tuberculosis, virus Chikungunya, virus denge, virus majmunskih boginja, herpes simpleks 1, herpes simpleks 2, Epstein-Barrov virus (EBV), poliovirus, virus influence ili Clostridium tetani.
a set of boxes and housings, particularly suitable to contain medical emergency material, available to support any possible emergency and assistance to people involved in car accidents, or natural disasters, like i.e. 
- < komplet kutija i pretinaca, osobito prikladnih da sadrže medicinski materijal za iznenadnu opasnost, materijal raspoloživ za pomoć u bilo kojoj mogućoj iznenadnoj opasnosti i pomoć osobama uključenim u automobilske nezgode ili prirodne katastrofe, kao što su na pr.
Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art. 
Primjeri sastava za nazalne aerosole ili unos inhalacijom uključuju otopine u slanoj vodi koje mogu sadržavati, npr., benzilni alkohol ili druge prikladne konzervanse, apsorpcijske promotore za povećanje biološke dostupnosti, i/ili druga sredstva za topivost ili disperziju kao što su ona poznata u struci.
A compound of formula (I): 
Spoj s formulom (I): m?
pilocarpine, methimazole and at least one additional active compound which is selected from baclofen, mifepristone, sorbitol and naltrexone; pilocarpine, methimazole and baclofen; 
Sastav u skladu s bilo kojim od patentnih zahtjeva 1 do 9, koji obuhvaća metimazol, pilokarpin, baklofen, mifepriston, sorbitol i naltrekson.
Table 11: Results of the filtration. 
Broj objave europskog patenta:
The organic solution was dried (sodium sulfate), filtered to remove solids, and concentrated in vacuo to give intermediate 27 as a brown oil. 
Organska otopina je sušena (natrij sulfat), filtrirana da bi se uklonile čvrste supstance 1 koncentrirana in vacuo da bi se dobio Intermedijer 27 kao smeđe ulje.
The contents of the juicer 1003 are then blended thereby causing the resulting juice to move from the bore 1003 into the container body 1002 through the sieve elements 114 . 
Sadržaj sokovnika 1003 se tako miješa i nastali sok se pomiče iz zapremine 1003 u tijelo posude 1002 kroz dijelove za prosijavanje 114.
Further provided is a method of treating a subject with an infectious disease, or at risk of becoming infected with an infectious disease, or with cancer, or at risk of developing cancer, by selecting a subject in need of treatment and administering to the subject a recombinant RhCMV or HCMV vector, or composition thereof, disclosed herein. 
Rekombinantni vektor RRCMYV ili HCMV u skladu s bilo kojim od patentnih zahtjeva 1-11, ili pripravak u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u postupku liječenja subjekta sa zaraznom bolešću, ili je u opasnosti od zaražavanja zaraznom bolešću, ili s rakom, ili je u opasnosti od razvoja raka.
This invention also relates to compounds of Formula (I)(A), wherein A is a 5-membered heterocyclic ring, which may contain 0-2 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, —C(O)Ra, —SO2Ra, arylalkyl, —(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, in which each Ra is independently C1-C6alkyl, substituted C1-C6alkyl or unsubstituted C3-C7cycloalkyl; each R2 and R3 is independently hydrogen, C1-C6alkyl, substituted C1-C6alkyl, halo, hydroxyl, amide, carboxylic acid or C1-C4alkoxy; 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što je A 5-eročlani heterociklički prsten, koji može sadržavati 0-2 dvostruke veze i može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine C;-Cgalkil, supstituirani C;-Cgalkil, C3-Czcikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, -SO>R., arilalkil, (C;-C;alkiljariloksi, aril, heteroaril i C;-Cgalkoksi, gdje je svaki R, neovisno C;-CÂ«alkil, supstituirani C;- Csalkil ili nesupstituirani C2-Crcikloalkil; svaki R> i R3 je neovisno vodik, C,-Cgalkil, supstituirani C,-Cgalkil, halogen, hidroksil, amid, karboksilna kiselina ili C,-C,alkoksi;
Formulation Example Tablets The ingredients below were mixed by an ordinary method and compressed by using a conventional apparatus. 
(1) Tablete Sastojci, niže, pomiješani su uobičajenim postupkom, te komprimirani konvencionalnim uređajem.
6 shows a chromatogram of beta-galactosidase capture on a MEP-HYPERCEL® column. 
Slika 6 prikazuje kromatogram hvatanja beta-galaktozidaze na koloni MEP HyperCel.
The ASM for use of claim 13, wherein the method further comprises a sequential dose of 3 mg/kg rhASM in the escalating dose regimen. 
KSM za uporabu u skladu s patentnim zahtjevom 13, pri čemu nadalje metoda sadrži sekvencijalnu dozu od 3 mg/kg ThKSM u režimu povećavanja doze.
a second substantially hydrophobic intermediate spacing layer 12, for transferring liquid-phase perspiration from the first inner layer 11 toward a third outer layer 13, said second layer 12 forming preferential passages, described in greater detail hereinafter, for the passage of the vapor-phase perspiration from the first layer 11 toward the outside, 
- < drugog međusloja za održavanje razmaka (12, 112, 212, 412), koji je u biti hidrofoban 1 prenosi tekuću fazu znoja 1z prvog unutarnjeg sloja (11, 111,211, 411) prema trećem vanjskom sloju (13, 113, 213),
The compound is administered once per day for five days every three weeks. 
Spoj se daje jednom dnevno u pet dana svaka tri tjedna.
is selected from the group consisting of an optionally substituted aryl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl; 
R* je odabran iz skupine koju čine po izboru supstituiran aril, po izboru supstituiran cikloalkil, po izboru supstituiran cikloalkenil, po izboru supstituiran heteroaril i po izboru supstituiran heterociklil;
A method according to claim 11, wherein R1 represents C1-6alkyl. 
Spoj sukladno patentnom zahtjevu 10 naznačeno time, da R1 predstavlja C1-6alkil.
Imaging agents of the invention may be used in accordance with the methods of the invention by one of skill in the art. 
Tvar u skladu s patentnim zahtjevom 14 za uporabu u metodi za liječenje tumora.